References
  1. Shirkey H. Editorial comment: Therapeutic orphans. The Journal of Pediatrics, 1968: 72(1): 119-120.
  2. Institute of Medicine. Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Washington DC: The National Academies Press. https://doi.org/10.17226/13311; 2012.
  3. PREA. Pediatric Research Equity Act (PREA). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK3997/
  4. BPCA. Best Pharmaceuticals for Children’s Act (BPCA). Retrieved from https://bpca.nichd.nih.gov/Pages/default.aspx
  5. Yondelis. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207953s005lbl.pdf
  6. Abraxane. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021660s046lbl.pdf
  7. Jevtana. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/201023s023lbl.pdf
  8. Velcade. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf
  9. Afinitor. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf
  10. Treanda. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022249s024lbl.pdf
  11. Tasigna. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022068s031lbl.pdf
  12. Taxotere. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020449s083lbl.pdf
  13. Sutent. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021938s036lbl.pdf
  14. Methotrexate. USP. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011719s125lbl.pdf
  15. Xeloda. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020896Orig1s042lbl.pdf
  16. Eloxatin. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021759s023lbl.pdf
  17. Cosmegen. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050682s034lbl.pdf
  18. Zometa. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021223s041lbl.pdf
  19. phosphate. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022137s003lbl.pdf
  20. Camptosar. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020571s051lbl.pdf
  21. Temodar. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022277s013lbl.pdf
  22. Navelbine. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020388s037lbl.pdf
  23. Gemzar. USPI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf
  24. RACE. Retrieved from https://www.congress.gov/bill/114th-congress/senate-bill/3239
  25. Barone A, Casey D, McKee A, Reaman G. Cancer Drugs approved for use in children: Impact of legislative initiatives and future opportunities. Pediatric Blood and Cancer. 2019: 66(8): e27809
  26. Ye, J. (2019). Ahead of FDARA Sec. 504 Implementation: Years in Review and Years Ahead in Pediatric Cancer Clinical Trials. Retrieved from https://ness-photos.s3.amazonaws.com/NERDS2019/slides/session_2/1.+Ye+-+PedRare_cancers_final.ppt